HK$43.62
7.82%
Hong Kong, Oct 13, 04:08 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG4790P1037
Symbol
3696

InSilico Medicine Cayman TopCo Stock price

HK$47.32
-4.58 8.82% 1M
-13.23 21.85% 6M
+10.18 27.41% YTD
+17.34 57.84% 1Y
+17.34 57.84% 3Y
+17.34 57.84% 5Y
+17.34 57.84% 10Y
+17.34 57.84% 20Y
Hong Kong, Closing price Mon, Oct 12 2026
-1.68 3.43%

Is InSilico Medicine Cayman TopCo a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,114 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$28.7b
Enterprise Value
HK$24.2b
Net debt
positive
Cash
HK$4.6b
Shares outstanding
575.8m
Valuation
P/E
negative
P/S | estimate
27.0 | 19.9
EV/Sales | estimate
22.9 | 16.9
EV/FCF | ex SBC
- | -
P/B
6.7
Financial Health
Equity Ratio
92.3%
Return on Equity
-77.9%
ROCE
-1.3%
ROIC
81.4%
Debt/Equity
0.0
Financials
Revenue | estimate
HK$1.1b | HK$1.4b
EBITDA
-
EBIT
HK$-57.2m
Net Income
HK$-2.3b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | 225.7%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
87.9%
EBITDA
-
EBIT
-5.4%
Net
-220.3%
Free Cash Flow | ex SBC
- | -
More
EPS
HK$-4.2
FCF per Share
-
Short interest
-
Employees
-
Rev per Employee
-

InSilico Medicine Cayman TopCo Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a InSilico Medicine Cayman TopCo forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a InSilico Medicine Cayman TopCo forecast:

Buy
93%
Hold
7%

Financial data from InSilico Medicine Cayman TopCo

Jun '26
+/-
%
1,060 1,060
-
100%
- Direct Costs 128 128
-
12%
932 932
-
88%
- Selling and Administrative Expenses 259 259
-
24%
- Research and Development Expense 747 747
-
70%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -57 -57
-
-5%
Net Profit -2,335 -2,335
-
-220%

In millions HKD.

Don't miss a Thing! We will send you all news about InSilico Medicine Cayman TopCo directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. The company employs 317 full-time employees The company went IPO on 2025-12-30. The firm is engaged in the research and development of drug discovery engines. In addition, the Company is engaged in the copabdrug discovery and development of disease target identification, generation of novel molecules data, and predicting clinical trial outcomes.

Head office Hong Kong
Website www.insilico.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today